Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Researchers Develop Low-cost Sickle Cell Anemia Screening Test for Developing Countries

Sickle cell anemia (SCA) is associated with lifelong complications and a high mortality rate in developing countries. Researchers have now developed a low-cost paper-based diagnostic test that allows clinicians to diagnose SCA earlier, significantly reducing the burden of the disease sickle cell anemia in resource-limited areas. The research paper, “Validation…

Hydroxyurea Therapy Use in Children with Sickle Cell Anemia in New York Explored in Study

Researchers investigated the use of hydroxyurea, a drug approved to treat sickle cell anemia in adults, in young children in New York State who are receiving this treatment. The findings reveal that pediatric use of hydroxyurea is widespread and increasing, but that incomplete adherence may limit the treatment’s full disease-modifying effects. The study,…

Process for Improving Risk Assessment of Stroke in Sickle Cell Anemia Kids Developed by Researchers

Researchers developed a project using what are termed “quality improvement methods” to increase the number of sickle cell anemia (SCA) babies and toddlers between the ages of 24-27 months who undergo transcranial Doppler ultrasonography (TCD) to detect the risk of stroke. The findings show the intervention resulted in significantly improved TCD…

US-based Biopharma Presents Positive Data on Potential Sickle Cell Therapy at European Hematology Congress

Global Blood Therapeutics, a biopharma developing novel therapeutics for the treatment of blood-based disorders, recently announced new results from its ongoing Phase 1/2 study of GBT440-001 in sickle cell disease (SCD). The data, presented at the European Hematology Association’s 21st Congress in Copenhagen, further supports the company’s plans to develop GBT440 as a…